Intensive chemotherapy improved survival in patients with accelerated and blast phase myeloproliferative neoplasms, with ...

Detailed price information for Legend Biotech Corp ADR (LEGN-Q) from The Globe and Mail including charting and trades.

Company reports Q2 2025 AUCATZYL® net product revenue of $20.9 million and $29.9 for the first six months of 2025Company recently received conditional marketing authorization from U.K. Medicines and ...

Among Janus kinase (JAK) inhibitor-naïve patients with myelofibrosis, treatment with the combination of pelabresib and ...

Company reports Q2 2025 AUCATZYL® net product revenue of $20.9 million and $29.9 for the first six months of 2025Company recently received conditional marketing authorization from U.K. Medicines and ...

Investing.com -- Beam Therapeutics Inc. (NASDAQ:BEAM) stock surged 12% after the company announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy ...

The CAR-T treatment GLPG5101 received the FDA's RMAT designation by showing promising efficacy with rapid delivery and low toxicity in mantle cell lymphoma.

Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 47% with 32% of patients achieving MMR by 24 weeks and ...

Continuing his interview about these results, CEPHEUS lead investigator Saad Z. Usmani, MD, MBA, FACP, FASCO, highlights the minimal residual disease negativity findings.

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the second quarter ended June 30, 2025 ...

Detailed price information for Disc Medicine Inc (IRON-Q) from The Globe and Mail including charting and trades.

Q2 2025 Earnings Call Transcript August 12, 2025 ADC Therapeutics S.A. misses on earnings expectations. Reported EPS is $-0.5 ...